{
    "nct_id": "NCT05549297",
    "official_title": "Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)",
    "inclusion_criteria": "* HLA-A*02:01-positive\n* unresectable Stage III or Stage IV non-ocular melanoma\n* archival tumor tissue sample or a newly obtained biopsy of a tumor lesion not previously irradiated has been provided.\n* measurable or non-measurable disease per RECIST 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* If applicable, must agree to use highly effective contraception\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed Consent (ICF) and protocol\n* Must agree to provide protocol specified samples for biomarker analyses.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant or lactating women\n* diagnosis of ocular or metastatic uveal melanoma\n* history of a malignant disease other than those being treated in this study\n* ineligible to be retreated with pembrolizumab due to a treatment-related AE\n* known untreated or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis\n* previous severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)\n* active autoimmune disease requiring immunosuppressive treatment with clinically significant cardiac disease or impaired cardiac function\n* known psychiatric or substance abuse disorders\n* received prior treatment with a licensed or investigative Immune-mobilizing monoclonal T-cell receptor Against Cancer (ImmTAC) medication who have not completed adequate washout from prior medications.\n* received chemotherapy or biological cancer therapy (excluding anti-PD(L)1 mAb, ipilimumab, and BRAF TKI regimen) within 14 days of first dose\n* received cellular therapies within 90 days of study intervention\n* ongoing Common Terminology Criteria for Adverse Events(CTCAE) Grade â‰¥ 2 clinically significant who in the opinion of the investigator could affect the outcome of the study\n* received systemic treatment with steroids or any other immunosuppressive drug within 2 weeks of first dose\n* have not progressed on treatment with an anti-PD(L)1 mAb\n* have not received prior treatment with an approved anti-CTLA-4 mAb\n* a BRAF V600 mutation, who have not received a prior BRAF/MEK TKI regimen\n* currently participating or have participated in a study of an investigational agent or using an investigational device within 30 days of the first dose\n* known history of chronic viral infections such as hepatitis B virus (HBV) or hepatitis C virus (HCV)\n* Out of range Laboratory values\n* history of allogenic tissue/solid organ transplant",
    "miscellaneous_criteria": ""
}